Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 2/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | MTOR | P42345 | 2/20 | 0.30 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.30 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272809 | 0.82 | PDE10A (0.46) | PDE10APDE4AKCNH2PARP1PARP2 | |
| SCHEMBL27975333 | 0.81 | TRPV4 (0.35) | KCNH2TKT | |
| SCHEMBL12776127 | 0.81 | ESR1 (0.45) | PDE10AHDAC1PDE4AKCNH2PARP1 | |
| SCHEMBL131690 | 0.79 | PPARD (0.36) | KCNH2ALDH1A1CCR9 | |
| SCHEMBL129948 | 0.76 | TRPV4 (0.52) | KCNH2TKTPIK3CA | |
| SCHEMBL31481176 | 0.75 | CA2 (0.43) | HDAC1CCR9 | |
| SCHEMBL133858 | 0.74 | TGFBR1 (0.34) | PDE10APDE4AKCNH2SYK | |
| SCHEMBL27855769 | 0.73 | KDM1A (0.35) | KCNH2TKT | |
| SCHEMBL127774 | 0.72 | LOXL2 (0.41) | ALDH1A1 | |
| SCHEMBL24922323 | 0.71 | DEGS1 (0.38) | SYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PDE10A 1813/4885HDAC1 561/4885PDE4A 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.